Does ELACESTRANT Cause Malignant neoplasm progression? 128 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 128 reports of Malignant neoplasm progression have been filed in association with ELACESTRANT (ORSERDU). This represents 1.9% of all adverse event reports for ELACESTRANT.
128
Reports of Malignant neoplasm progression with ELACESTRANT
1.9%
of all ELACESTRANT reports
2
Deaths
22
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ELACESTRANT?
Of the 128 reports, 2 (1.6%) resulted in death, 22 (17.2%) required hospitalization, and 2 (1.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELACESTRANT. However, 128 reports have been filed with the FAERS database.
What Other Side Effects Does ELACESTRANT Cause?
Nausea (1,454)
Fatigue (1,081)
Disease progression (777)
Vomiting (662)
Diarrhoea (540)
Death (499)
Drug ineffective (478)
Constipation (389)
Product dose omission issue (364)
Decreased appetite (363)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ELACESTRANT Alternatives Have Lower Malignant neoplasm progression Risk?
ELACESTRANT vs ELAFIBRANOR
ELACESTRANT vs ELAGOLIX
ELACESTRANT vs ELAGOLIX\ESTRADIOL\NORETHINDRONE
ELACESTRANT vs ELAPEGADEMASE-LVLR
ELACESTRANT vs ELASOMERAN